Welcome to our dedicated page for Cidara Theraptcs SEC filings (Ticker: CDTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cidara Therapeutics, Inc. (CDTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a former Nasdaq-listed biotechnology issuer. These documents include current reports on Form 8-K, financing-related filings, and other materials that describe Cidara’s clinical development plans, capital structure changes, government agreements, and its acquisition by Merck.
For investors and researchers analyzing Cidara’s business, the company’s 8-K filings are especially important. They detail key events such as the Agreement and Plan of Merger with Merck Sharp & Dohme LLC and a Merck subsidiary, the terms of the cash tender offer for all outstanding shares of common and Series A preferred stock, and the planned merger that will make Cidara a wholly owned subsidiary of Merck. These filings also outline conditions to closing, tender offer mechanics, termination fees, and other transaction terms.
Other 8-K reports describe Cidara’s clinical and regulatory progress with CD388. For example, filings explain updates to the planned Phase 3 registrational trial following an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), including expansion of the ANCHOR study population and the intention to seek biologics license application (BLA) approval based on a single Phase 3 study. Additional filings summarize positive topline results from the Phase 2b NAVIGATE trial and provide context on safety and prevention efficacy data.
Cidara’s filings also cover its Award/Contract with the Biomedical Advanced Research and Development Authority (BARDA) to support expanded manufacturing and clinical development of CD388, including base-period funding for onshoring manufacturing to the United States and potential option funding for further studies. Capital markets transactions, such as underwritten public offerings of common stock and suspension of an at-the-market (ATM) prospectus, are documented in 8-Ks that describe underwriting agreements, share issuance, and related legal opinions.
On Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that highlight the main points of each document. Users can quickly see what each 8-K, registration-related filing, or other report means for Cidara’s clinical programs, financing, and merger process. While Cidara’s common stock is expected to cease trading on the Nasdaq Global Market following completion of its merger with Merck, its historical filings remain a key resource for understanding the evolution of CD388, the Cloudbreak platform, and the corporate steps leading to the acquisition.
Cidara Therapeutics, Inc. is being removed from listing and registration on the Nasdaq Stock Market LLC for its common stock. Nasdaq certifies that it has followed its own rules under 17 CFR 240.12d2-2(b) to strike this class of securities from listing and/or withdraw its registration. The filing also notes that Cidara has complied with the exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) for voluntary withdrawal of the common stock from listing and registration.
Cidara Therapeutics, Inc. has completed its sale to Merck Sharp & Dohme LLC via a tender offer and follow-on merger, and will cease to be a publicly traded company. Merck’s subsidiary acquired Cidara shares for $221.50 per common share and $15,505.00 per Series A preferred share, all in cash, without interest and subject to taxes. The offer expired January 6, 2026, with approximately 88.3% of voting power tendered, plus additional shares under guaranteed delivery, satisfying the minimum tender condition and allowing the merger to close without a stockholder vote.
At the effective time, remaining common and Series A shares were converted into the same cash amounts, Cidara’s stock options and restricted stock units were cashed out based on the common share price (underwater options were canceled), and warrants were treated as cashless exercised. Cidara terminated its equity and employee stock purchase plans, became a wholly owned Merck subsidiary, requested delisting of its common stock from Nasdaq, and plans to deregister its shares and suspend SEC reporting. The board and officers were replaced by Merck designees, and Cidara’s charter and bylaws were fully amended and restated.
Cidara Therapeutics filed an amendment confirming completion of Merck’s cash acquisition through a tender offer and merger. Merck offered $221.50 in cash for each Cidara common share and $15,505.00 in cash for each Series A Convertible Voting Preferred share, both without interest and subject to withholding taxes.
As of the offer’s expiration on January 6, 2026, 27,149,333 common shares and 89,956 Series A shares had been validly tendered and not withdrawn, representing approximately 88.3% of shares entitled to vote on an as-converted basis, satisfying the minimum tender condition. The merger closed on January 7, 2026, making Cidara a wholly owned subsidiary of Merck. Cidara’s common stock will be delisted from the Nasdaq Capital Market, and Merck intends to terminate its registration and suspend Cidara’s reporting obligations under the Exchange Act.
Cidara Therapeutics, Inc. reported an insider stock transfer by its Chief Medical Officer on a Form 4. On 12/29/2025, the officer made a bona fide gift of 450 shares of common stock to a donor-advised fund for charitable purposes, with no beneficial ownership or control retained over the donated shares. Following this transaction, the officer beneficially owns 20,886 shares of Cidara common stock, which includes 50 shares acquired through the company’s Employee Stock Purchase Plan on December 18, 2025.
Caymus Purchaser, Inc., an indirect subsidiary of Merck, filed an amendment updating its cash tender offer for all common and Series A preferred shares of Cidara Therapeutics, Inc.. The offer price remains $221.50 per common share and $15,505.00 per Series A preferred share, both payable in cash, without interest and subject to withholding taxes. The amendment clarifies that, based on shares outstanding as of December 3, 2025, the minimum condition is expected to be met if approximately 18,900,605 shares (a majority of common and Series A on an as-converted basis) are validly tendered and not withdrawn by the expiration date. It also states that, as of December 12, 2025, Merck, Parent, Purchaser and their directors and executive officers did not beneficially own Cidara shares or trade in them during the prior 60 days, and it refines language on how offer conditions relate to rights under the merger agreement.
Cidara Therapeutics’ Chief Financial Officer reported a change in ownership of company common stock. On December 10, 2025, a transaction coded “F” involved 7,290 shares of common stock at $219.6 per share, identified as shares withheld to satisfy taxes upon RSU vesting.
Following this transaction, the officer directly owned 50,562 shares of Cidara Therapeutics common stock. This amount includes 352 shares acquired through the company’s Employee Stock Purchase Plan on November 20, 2025.
Cidara Therapeutics reported insider stock transactions by its COO & CLO. On December 10, 2025, 15,041 common shares were withheld to cover taxes on restricted stock unit vesting at $219.6 per share. The officer exercised employee stock options to purchase 3,500 shares at $16.654 and 6,459 shares at $20.2, and sold 9,959 shares at $220.077 per share. Following these transactions, the officer directly owned 25,033 common shares, including 400 acquired through the employee stock purchase plan, and held 6,207 stock options, with all share amounts adjusted for a 1-for-20 reverse stock split effective April 24, 2024.
Cidara Therapeutics’ Chief Medical Officer reported a routine insider stock transaction. On 12/10/2025, 10,332 shares of common stock were disposed of to cover taxes due on restricted stock unit vesting, as explained in the footnotes. After this tax withholding, the officer beneficially owned 21,286 common shares directly, which includes 200 shares acquired through the company’s Employee Stock Purchase Plan on November 20, 2025.
Cidara Therapeutics agreed to be acquired by Merck Sharp & Dohme via an all‑cash tender offer, followed by a merger under DGCL Section 251(h). Merck will commence the offer no later than December 4, 2025 to purchase Cidara common stock at $221.50 per share and Series A preferred at $15,505.00 per share, in cash, without interest and subject to withholding.
The offer is conditioned on more than 50% of outstanding shares (including Series A on an as‑converted basis) being tendered, and on receipt or expiration of required antitrust clearances. There is no financing condition. After the offer, Cidara will merge into a Merck subsidiary and become a wholly owned unit.
At closing, options vest and are cashed out for any in‑the‑money value; RSUs are cashed out at the common offer price; and warrants are deemed cashless exercised per their terms. Support agreements commit certain stockholders to tender and vote in favor. The agreement includes a $300,563,308 termination fee payable by Cidara in specified cases and a $462,405,090 reverse termination fee payable by Merck in certain antitrust‑related or timing scenarios, with an End Date of May 13, 2026.
Caymus Purchaser, Inc., a wholly owned subsidiary of Merck Sharp & Dohme LLC, announced plans to commence a tender offer to acquire all outstanding shares of Cidara Therapeutics, Inc. (CDTX), including its common stock and Series A Voting Convertible Preferred Stock, pursuant to an Agreement and Plan of Merger dated November 13, 2025.
The tender offer has not yet commenced. When launched, Merck and Caymus Purchaser will file a Schedule TO with an offer to purchase and related documents, and Cidara will file a Schedule 14D‑9 stating its position. Investors will be able to access these materials on SEC.gov. The filing includes forward‑looking statements and notes potential conditions and risks, including the need for a sufficient number of tendered shares and other customary closing conditions.